Intelligent Scopes Corp, Subsidiary of Claritas HealthTech, to Lead Global Delivery of CystoSmart™, an AI-Assisted Diagnostic Software for Bladder Cancer Detection in Endoscopic Images
12 nov. 2023 19h13 HE
|
Claritas HealthTech Ltd
Intelligent Scopes Corp, Subsidiary of Claritas HealthTech, to Lead Global Delivery of CystoSmart™, an AI-Assisted Diagnostic Software for Bladder Cancer
Bladder Cancer Treatment Market is expected to hit USD 7.52 Bn by 2029 at a CAGR of 9.2 percent – says Maximize Market Research
30 mai 2023 08h08 HE
|
MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, May 30, 2023 (GLOBE NEWSWIRE) -- A global Healthcare research and business-consulting firm, Maximize Market Research, has published a market intelligence report on the “Bladder Cancer...
Theralase® Releases FY2022 Audited Financial Statements
26 avr. 2023 18h01 HE
|
Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
23 févr. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Criterium, Inc. Announces Formation of New Oncology Research Consortium for Genito-Urinary Indications
26 janv. 2023 09h30 HE
|
Criterium Inc.
SARATOGA SPRINGS, N.Y., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium
25 janv. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase Releases Q222 Interim Financial Statements
29 août 2022 19h45 HE
|
Theralase Technologies Inc.
TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Expands Intellectual Property Portfolio
28 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
24 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase Ib NMIBC Clinical Study Published
21 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...